Veraxa Biotech AG (VRXA)
| Market Cap | 34.04M -89.7% |
| Revenue (ttm) | 29,543 |
| Net Income | -84.01M |
| EPS | -5.80 |
| Shares Out | 25.22M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 315,715 |
| Open | 1.430 |
| Previous Close | 1.440 |
| Day's Range | 1.320 - 1.450 |
| 52-Week Range | 1.320 - 27.360 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About VRXA
Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.... [Read more]
News
Veraxa Biotech, Secarna announce initial results from AOC alliance
Veraxa Biotech (VRXA) and Secarna Pharmaceuticals announced initial results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates for the treatment...
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates
ZURICH, SWITZERLAND, July 29, 2026 (GLOBE NEWSWIRE) -- VE RAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided an update on its core patent ...
Veraxa Biotech advances VXA-222 following milestone in OmniAb pact
Veraxa Biotech (VRXA) announced the advancement of bispecific ADC program VXA-222, following successful achievement of a key technical milestone in its alliance with OmniAb (OABI). The program is movi...
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
VERAXA Biotech's and OmniAb's bispecific ADC program VXA-222 advances into next phase at VERAXA following the achievement of a key technical milestone.
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth
ZURICH, SWITZERLAND , July 24, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in the design and development of next-generation cancer therapeutics, held an Ext...
Veraxa Biotech appoints Christoph Erkel as chief scientific officer
Veraxa Biotech (VRXA) announced the appointment of Christoph Erkel as chief scientific officer, effective immediately. Christoph Erkel, previously VP of research and development at Veraxa Biotech, wil...
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio
ZURICH, SWITZERLAND, July 23, 2026 (GLOBE NEWSWIRE) -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of Christoph ...
VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan
ZURICH, SWITZERLAND – July 20, 2026 – VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA), an emerging leader in designing novel cancer therapies, today announced that it has received Scientific Advice from the...
Veraxa Biotech announces BiTAC pipeline collaboration with Ardigen
Veraxa Biotech (VRXA) announced a collaboration with Ardigen to support Veraxa’s growing BiTAC pipeline of t cell engagers and antibody drug conjugates. The partnership with Ardigen will initially foc...
VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline
ZURICH, SWITZERLAND – July 13, 2026 -- VE RAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-dri...
Veraxa CFO Torsten Burgermeister steps down, Carl von Halem named interim CFO
Veraxa Biotech (VRXA) announced the appointment of Carl von Halem as interim CFO. He succeeds Torsten Burgermeister. The company is currently in the final stages of discussions with a successor.
VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Bürgermeister
ZURICH, SWITZERLAND – July 10, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the appointment of Carl von Halem as Interim ...
Veraxa Biotech provides pipeline and partnering strategy update
Veraxa Biotech (VRXA) provided a company and pipeline update, highlighting its strategic focus on its proprietary BiTAC platform. The company intends to channel the majority of its investments into it...
VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines
ZURICH, SWITZERLAND – July 6, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today provided a company and pipeline update. “In the first si...
Veraxa Biotech initiates cell line development for BiTAC T-cell engager program
Veraxa Biotech (VRXA) announced the initiation of cell line development for its BiTAC T-cell engager program. Veraxa has engaged Atum to apply the proprietary Leap-In Transposase technology to support...
VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC®-TCE Program
ZURICH, SWITZERLAND – July 02, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced the initiation of cell line development for i...
Veraxa Biotech expands R&D site in Germany
Veraxa Biotech (VRXA) announced that the company has moved into additional laboratory space at its existing R&D site in Heidelberg, Germany, based on a previously signed long-term lease agreement. The...
VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC™-TCE and ADC Programs Advance Towards Clinical Development
VERAXA Biotech has moved into additional laboratory space at its R&D site in Heidelberg, Germany, based on a previously signed long-term lease agreement.
Veraxa Biotech establishes in vitro proof-of-concept for BiTAC-ADC platform
VERAXA Biotech (VRXA) announced that the Company has generated new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform and its potential to enable more precise and target...
VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026
ZURICH, SWITZERLAND – June 18, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced that the Company has generated new in vitro p...
Veraxa Biotech AG trading resumes
11:07 EDT Veraxa Biotech (VRXA) AG trading resumes
Veraxa Biotech AG trading halted, volatility trading pause
10:57 EDT Veraxa Biotech (VRXA) AG trading halted, volatility trading pause